CashuRepatha®'s Cardiovascular Benefits Highlighted for High-Risk Diabetes Patients in Recent Study8 days ago
CashuAmgen Under Pressure to Enhance Drug Affordability Amid Industry Challenges and Innovations15 days ago
prnewswire.comREPATHA CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS8 days ago
benzinga.comPrivate Credit's $1.8 Trillion Illusion Breaks: The Liquidity Crunch No One Was Ready For17 days ago
cnbc.comFDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share17 days ago
benzinga.comMark Cuban Refuses To 'Rip On' TrumpRx, Lauds It For Saving 'A Lot Of ' Patients' Money17 days ago
benzinga.comAmgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report20 days ago